Is Somatostatin Receptor and Dopamine Receptor profiling useful in the management of silent somatotroph tumors?

Silent somatotroph tumors (sSTs) are pituitary neuroendocrine tumors (PitNETs) which do not give rise to the clinical syndrome of acromegaly. Differently to their functioning counterparts, the adjuvant medical treatment with somatostatin analogues (SSAs) or dopamine receptors agonists (DAs) has been...

Full description

Saved in:
Bibliographic Details
Published in:Journal of endocrinological investigation 2020-06, Vol.43 (6), p.859-863
Main Authors: Martínez-López, S., García-Martínez, A., Torregrosa-Quesada, M. E., López-Muñoz, B., Cámara, R., Fajardo, C., Lamas, C., Picó, A.
Format: Article
Language:English
Subjects:
Acromegaly
Adenoma - diagnosis
Adenoma - genetics
Adenoma - metabolism
Adult
Biomarkers, Tumor - biosynthesis
Biomarkers, Tumor - genetics
Comment
Disease Management
Dopamine
Dopamine D2 receptors
Dopamine receptors
Endocrinology
Female
Gene Expression Profiling - methods
Humans
Internal Medicine
Male
Medical treatment
Medicine
Medicine & Public Health
Metabolic Diseases
Middle Aged
Neuroendocrine tumors
Neuroendocrine Tumors - diagnosis
Neuroendocrine Tumors - genetics
Neuroendocrine Tumors - metabolism
Pituitary
Pituitary Neoplasms - diagnosis
Pituitary Neoplasms - genetics
Pituitary Neoplasms - metabolism
Receptors, Dopamine D2 - biosynthesis
Receptors, Dopamine D2 - genetics
Receptors, Somatostatin - biosynthesis
Receptors, Somatostatin - genetics
Somatostatin
Somatotrophs - metabolism
Somatotrophs - pathology
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Silent somatotroph tumors (sSTs) are pituitary neuroendocrine tumors (PitNETs) which do not give rise to the clinical syndrome of acromegaly. Differently to their functioning counterparts, the adjuvant medical treatment with somatostatin analogues (SSAs) or dopamine receptors agonists (DAs) has been scarcely addressed in these tumors. As preliminary results of an ongoing research on silencing mechanisms involved in the pathogenesis of sSTs, we have characterized by qRT-PCR the expression of SSTRs and DRDs in a large series of 18 silent and 68 functioning STs. Although the expression of SSTR2 and SSTR5 was lower in sSTs than in functioning ones, we found a negative correlation between SSTR2 and the tumor size of the sSTs. Additionally, levels of expression of DRD2 were similar between the two subtypes suggesting a possible basis for the treatment of these tumors with SSAs and DAs.
ISSN:1720-8386
0391-4097
1720-8386
DOI:10.1007/s40618-019-01166-8